John Theurer Cancer Center ku Hackensack University Medical Center yalengeza lero kuti yathandiza wodwala woyamba mdziko muno ndi DSP-0390, mankhwala ofufuza a relapsed glioblastoma (GBM) ndi ma glioma ena apulasitiki.

Glioblastoma (GBM) ndi imodzi mwa mitundu yowopsa kwambiri ya khansa ya muubongo yomwe imabwereranso ngakhale mutalandira chithandizo chokhazikika monga chemotherapy ndi radiation. Kukhala ndi moyo kupitirira zaka zisanu n'kosowa, ndipo mankhwala atsopano amafunikira kwambiri.

DSP-0390, wothandizira watsopano wofufuza wopangidwa ndi Cambridge, Massachusetts-based Sumitomo Dainippon Pharma Oncology, ndi inhibitor ya emopamil-binding protein (EBP), molekyulu mu cholesterol biosynthesis. DSP-0390 sinavomerezedwe ndi US Food and Drug Administration komanso chitetezo chake ndi mphamvu zake sizinakhazikitsidwe.

"Matupi athu amafunikira cholesterol kuti amange maselo athanzi komanso kuti maselowo azitha kulumikizana," adatero Samuel A. Goldlust, MD, Medical Director wa Neuro-Oncology. "Koma ma cell a GBM amatha kukakamiza kupanga cholesterol kukhala mopitilira muyeso, zomwe zimapangitsa kukula kwa chotupa ndikuletsa EPB kuletsa kukula uku."

Kafukufuku wapadziko lonse lapansi wa Phase 1/2 wakonzedwa kuti alembetse odwala 70 m'malo asanu otupa muubongo ku US ndi Japan.

"Mayesero achipatala ku GBM atiphunzitsa kuti chithandizo chamankhwala sichikwanira kugonjetsa chotupa chovuta ichi," adatero George J. Kaptain MD, Mtsogoleri wa Neurosurgical Oncology. "Ndi mwayi waukulu kupatsa odwala athu mwayi wopeza njira zatsopano zochiritsira zomwe zimayang'aniridwa ndi maselo monga DSP -0390, pofunafuna chithandizo chothandizira kuti apulumuke komanso kuchepetsa zotsatirapo zake."

ZOMWE MUNGACHITE PA NKHANIYI:

“It is a privilege to be able to offer our patients streamlined access to novel, investigational molecularly targeted therapies like DSP -0390, in our ongoing pursuit of treatments to help maximize survival and minimize side effects.
DSP-0390, an investigational new agent developed by Cambridge, Massachusetts-based Sumitomo Dainippon Pharma Oncology, is an inhibitor of emopamil-binding protein (EBP), a molecule in cholesterol biosynthesis.
This multicenter, global Phase 1/2 study is planned to enroll 70 patients at five brain tumor centers in the U.